Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study by Nash, P, Coates, LC, Fleishaker, D, Kivitz, AJ, Mease, PJ, Gladman, DD, FitzGerald, O, Wang, C, Wu, J, Hsu, M-A, Menon, S, Fallon, L, Kanik, KS

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, pl... by Nash, P, Mease, PJ, Fleishaker, D, Wu, J, Coates, LC, Behrens, F, Gladman, DD, Kivitz, AJ, Wei, JC, Shirinsky, I, Menon, S, Romero, AB, Fallon, L, Hsu, MA, Wang, C, Kanik, KS

Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study by Nash, P, Coates, LC, Kivitz, AJ, Mease, PJ, Gladman, DD, Covarrubias-Cobos, JA, FitzGerald, O, Fleishaker, D, Wang, C, Wu, J, Hsu, M-A, Menon, S, Fallon, L, Romero, AB, Kanik, KS